High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients

Enrique Iglesias Julián,María López Veloso, Noelia de la Torre Ferrera, Julio Cesar Barraza Vengoechea,Pedro David Delgado-López, María Colazo Burlato, Marta Ubeira Iglesias, Miguel Montero Baladía, Andrés Lorenzo Martín,Javier Minguito de la Iglesia, Juan Pablo García Muñoz, Rodrigo Sanllorente Sebastián, Blanca Vicente González, Ana Alemán Alemán, Luis Buzón Martín

Journal of Autoimmunity（2020）

引用 58|浏览0

暂无评分

摘要

•A percentage of COVID-19 patients develop systemic hyperinflammation and cytokine storm syndrome (CSS).•COVID-19 related CSS may end up in acute respiratory distress syndrome (ARDS).•IL-1 plays a relevant role in such hyperinflammation state.•IL-1 inhibition by anakinra seems to be a promising treatment option for severely ill COVID-19 ARDS patients.

查看译文

关键词

IL-1,Anakinra,Tocilizumab,COVID-19,SARS-CoV2,Acute respiratory distress syndrome,Cytokine storm syndrome

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要